| Prostate Cancer |
1 |
1 |
| Cancer |
0 |
0.68 |
| Prostate |
0 |
0.57 |
| Biologic Therapy |
0 |
0.5 |
| Genomic Medicine |
0 |
0.42 |
| Prostate Specific Antigen |
0 |
0.39 |
| Tumor |
0 |
0.28 |
| Myelodysplastic Syndrome |
0 |
0.17 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.17 |
| Anemia |
0 |
0.11 |
| Chemotherapy |
0 |
0.11 |
| Pulmonary Embolism |
0 |
0.11 |
| Receptors |
0 |
0.11 |
| Tissue |
0 |
0.11 |
| Platelet Count |
0 |
0.1 |
| Thromboembolism |
0 |
0.09 |
| Acute Myeloblastic Leukemia |
0 |
0.08 |
| Acute Leukemia |
0 |
0.07 |
| Adverse Effects |
0 |
0.06 |
| Antigens |
0 |
0.06 |
| Breast |
0 |
0.06 |
| Canada |
0 |
0.06 |
| Embolism |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Fatigue |
0 |
0.06 |
| Genetics |
0 |
0.06 |
| Leukemia |
0 |
0.06 |
| Neutrophils |
0 |
0.06 |
| Pain |
0 |
0.06 |
| Spain |
0 |
0.06 |
| Utah |
0 |
0.06 |
| Fractures |
0 |
0.05 |
| Hypertension |
0 |
0.05 |
| Pain Management |
0 |
0.05 |
| Patient Safety |
0 |
0.05 |